![\"\"](\"https:\/\/images.newscientist.com\/wp-content\/uploads\/2024\/08\/16201540\/SEI_217612665.jpg\")
<\/div>Illustration of the mpox virus<\/p>\n
Getty Images\/Science Photo Library<\/p>\n<\/div>\n<\/figcaption><\/figure>\n<\/p>\n
The World Health Organization (WHO) has declared a public health emergency of international concern over an ongoing outbreak of mpox \u2013 formerly known as monkeypox<\/a> \u2013 in Central and West Africa. This is the second time in two years that the disease has spread enough to prompt such a declaration from the WHO<\/a>. On 15 August, Swedish health officials confirmed a case as the first known infection outside of Africa with the mpox strain that is currently driving the outbreak.<\/p>\n Mpox is an infectious disease caused by a virus that belongs to the same family as that which causes smallpox<\/a>. It regularly spreads among animals in Central and West Africa such as rodents and monkeys, but occasionally jumps to people, causing small outbreaks.<\/p>\n There are two distinct lineages of mpox: clade I and clade II<\/a>. Clade I is associated with more severe disease and higher risk of death. A subtype of clade I, called clade Ib, is driving the current outbreak, while the global mpox outbreak in 2022 and 2023 was spurred by a subtype of clade II.<\/p>\n So far, there is no evidence to suggest that clade Ib is more dangerous than the original clade I strain, said Jonas Albarnaz<\/a> at The Pirbright Institute in the UK in a statement.<\/p>\n <\/p>\n The Africa Centres for Disease Control and Prevention reported on 13 August<\/a> that there have been more than 17,000 suspected cases across the continent. \u201cThis is just the tip of the iceberg when we consider the many weaknesses in surveillance, laboratory testing and contact tracing,\u201d the agency said in the statement.<\/p>\n There have been 15,664 reported cases and 537 deaths so far in the Democratic Republic of the Congo alone, according to the WHO. This exceeds the total seen in 2023, according to a statement<\/a> by Tedros Adhanom Ghebreyesus at the WHO on 15 August.<\/p>\n The current outbreak originated in a small mining town<\/a> in the Democratic Republic of the Congo (DRC). The mpox variant has now spread to at least 11 other African countries, including four that had previously never reported mpox: Kenya, Rwanda, Burundi and Uganda. Mpox has also been detected in one person in Sweden.<\/p>\n While more than 99.9 per cent of people who fall ill with clade II survive, mpox outbreaks of clade I have killed up to 10 per cent of people who become sick. Children and people who are immunocompromised or pregnant are especially vulnerable to severe disease.<\/p>\n The first mpox symptom is usually a rash, which begins as a flat sore and then develops into a blister that may be itchy or painful. The rash tends to start on the face before spreading across the body and extending to hands and feet. People can also get lesions in their mouth or on the genitals or anus.<\/p>\n The rash and lesions usually last between two and four weeks and are often accompanied by other symptoms such as fever, headache, muscle aches, back pain, fatigue and swollen lymph nodes.\u00a0Symptoms usually begin within a week of contracting the virus but can start anywhere from one to 21 days after exposure. However, some people can contract the virus without experiencing symptoms.<\/p>\n Mpox is spread through close contact with people who have the illness. Usually this is through skin-to-skin contact, such as sex, kissing or touching. The virus can also spread through respiratory droplets and contact with contaminated materials such as bedsheets, other linens or sharp objects like needles. People remain infectious until all of their sores heal.<\/p>\n Mpox can also spread through contact with infected animals such as through bites or scratches, or when people hunt or eat them.<\/p>\n Young adults and children have been most affected by the current outbreak, a trend that was not seen in the 2022-2023 outbreak. In some provinces of the DRC, children under 15 account for up to 69 per cent of suspected cases<\/a>.<\/p>\n Treatment primarily consists of managing symptoms and preventing complications like secondary infections. Some antivirals that were originally developed for treating smallpox have also been used to treat mpox in the past. However, results from a recent trial of the antiviral drug tecovirimat, which was used in the previous outbreak, found that it was not effective against the clade I virus<\/a>. People who have mpox should self-isolate and wear a mask. They should also avoid scratching sores, which can prevent them from healing, increase the risk of secondary infections and cause them to spread to other parts of the body.<\/p>\n There is an mpox vaccine<\/a>, which provides the best protection after two doses. Smallpox vaccines have also been found to protect against mpox, though it isn\u2019t clear if any of these vaccines will be effective against the new mpox variant.<\/p>\n People are recommended to get vaccinated only if they are at high risk of contracting mpox. For people who aren\u2019t in areas affected by the current outbreak, the risk remains very low.<\/p>\n Countries in Africa currently have minimal to no vaccine supplies, though estimates suggest the region needs 10 million doses, said Jimmy Whitworth<\/a> at the London School of Hygiene & Tropical Medicine in a statement.<\/p>\n Topics:<\/p>\n<\/section><\/div>\nWhat is mpox?<\/h2>\n
How many cases of mpox have there been in 2024?<\/h2>\n
Where has mpox been detected?<\/h2>\n
What is the survival rate for mpox?<\/h2>\n
What are the symptoms of mpox?<\/h2>\n
How does mpox spread?<\/h2>\n
How is mpox treated?<\/h2>\n
Is there an mpox vaccine?<\/h2>\n